Funding Opportunities

Funder: Japan Agency for Medical Research and Development (AMED) and U.S. National Institute of Allergy and Infectious Diseases Viral Diseases and Immunology Research

2018 U.S. – Japan Cooperative Medical sciences program Collaborative awards

CRDF Global is accepting proposals from joint U.S., Japan, and other Regional Asia-Pacific (APac) based investigators working in the field of infectious disease and immunology research for the U.S.-Japan Cooperative Medical Sciences Program (USJCMSP) Collaborative Awards, 2018. This initiative is jointly conducted by CRDF Global utilizing funds provided by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) and the Japan Agency for Medical Research and Development (AMED).

USJCMSP Collaborative Awards, 2018 represents the second round of a collaborative award program that was initiated in 2016, following the 50th anniversary celebration of the USJCMSP. The awards program aims to promote the inclusion of early-career and female scientists in collaborative research.

The purpose of the USJCMSP collaborative awards is to foster new or expanded viral disease and immunology focused biomedical research collaborations between researchers in Japan, the APac region, and U.S. investigators and institutions.  It is expected that proposals will focus on questions of direct relevance to the APac region that will add to global knowledge about viral diseases and immunology.  The USJCMSP continues to promote collaborations, especially to include early-stage and female scientists from around the region.

Call budget: $50,000
Call opens: September 22, 2017
Application deadline: December 1, 2017
FIND OUT MORE

Funder: The Antimicrobial Resistance Ring-Fenced Initiative with strategic leadership from the Canadian Institutes of Health Research (CIHR) Institute of Infection and Immunity (III) and the Institute of Population and Public Health (IPPH)

Catalyst Grant: Global Governance of Antimicrobial Resistance and Related Infectious Disease Threats

The increasing emergence of antimicrobial resistance (AMR), in addition to the wide-spread epidemics and various infectious disease challenges, pose significant threats to the social, economic, and health security of communities and countries around the world.

The Grant will help to encourage and support collaborations across the range of social sciences currently studying the arrangements, systems, and institutions working to prevent, detect, and manage AMR and other infectious disease threats.

This funding opportunity will support the planning, catalyst, and pilot implementation of social science research projects focused on any topic relevant to improving our understanding of how to design and implement effective global governance arrangements, institutions, and/or structures for addressing AMR and related infectious disease threats.
Call budget: $600,000, enough to fund approximately 6 grants of up to $100,000 each for up to 1 year
Call opens: June 28, 2017
Application deadline: October 17, 2017
FIND OUT MORE

Funder: The European & Developing Countries Clinical Trials Partnership (EDCTP)

Treatment Innovations for Poverty-Related Diseases

Poverty-related diseases (PRDs) represent a major obstacle to the sustainable development of sub-Saharan Africa. There is limited availability of effective, safe, suitable and affordable products to diagnose and treat PRDs in sub-Saharan Africa, and the number of new chemical entities that are registered remains very low. There is therefore an urgent need to accelerate the development of new and improved products through the clinical development pipeline.

The purpose of this Call for Proposals is to provide funding for the clinical evaluation and development of new and innovative drug candidates for HIV/AIDS, malaria, tuberculosis, diarrhoeal infections or lower respiratory infections, including co-infections.

Call budget: € 30M
Call opens: July 3, 2017
Application deadline: September 5, 2017, 17:00

 

Strategic actions supporting large-scale clinical trials

The purpose of this Call for Proposals is to support strategic actions (clinical research activities) that are part of a large-scale clinical trial with the potential to achieve rapid advances in the clinical development of new or improved medical interventions (drugs, diagnostics, vaccines, microbicides) for PRDs.

Proposals for a strategic action should focus on phase III study(ies) on PRDs within the remit of the EDCTP2 programme. The proposed EDCTP-funded study(ies) should be conducted in sub-Saharan Africa but may form part of a larger trial that is conducted globally. The clinical trial must be supported by an appropriate regulatory approval and access strategy and/or include plans for uptake into policy and practice at national or international level.

Call budget: €43 M
Call opens: July 3, 2017
Application deadline: September 5, 2017, 17:00

 

Clinical trials to reduce health inequities in pregnant women, newborns and children

The objective of this call is to accelerate the adaption and/or optimisation of treatment and prevention products (excluding vaccines) for PRDs in sub-Saharan Africa for use in pregnant women, newborns and/or children. This call is restricted to the following diseases: HIV, malaria, tuberculosis, diarrhoeal diseases and lower respiratory infections.

Call budget: €38.23 M
Call opens: July 4, 2017
Application deadline: October 13, 2017, 17:00

 

Targeting control and elimination of NIDs through clinical trials

Neglected Infectious Diseases (NIDs, also known as Neglected Tropical Diseases) are a diverse group of diseases that affect an estimated 1.2 billion people worldwide. These diseases disproportionately affect the world’s poor, causing significant mortality and morbidity. Global investment into research and development of new products for NIDs is limited and there is an urgent need to develop new or improved products and to optimize the use of existing products in order to achieve disease elimination.

The objective of this Call for Proposals is to provide funding for clinical trials to accelerate the development of new or improved therapeutics for NIDs in sub-Saharan Africa.

Call budget: €18.8 M
Call opens: July 4, 2017
Application deadline: October 31, 2017, 17:00

 

Targeting control and elimination of NIDs through product-focused implementation research

The objective of this Call for Proposals is to provide funding for product-focused post-registration implementation studies for NIDs in sub-Saharan Africa.

Proposals should focus on implementation research studies to translate medical interventions (diagnostics, drugs for treatment and prevention) of proven efficacy into routine care, or on improving population coverage and access to the intervention, retention in care and/or adherence to the intervention.

Call budget: €11.2 M
Call opens: July 4, 2017
Application deadline:  November 2, 2017, 17:00

FIND OUT MORE

Funder: EU-LAC Health project

Topic 2: Infectious diseases – Research in promotion of well-being: prevention of infectious diseases, emerging food, water and vector borne diseases

The overall objective of this initiative is to develop bi-regional joint programming in health research and innovation.

More specifically this transnational Call for projects is focused on two topics with Topic 2 being of particular relevance with GloPID-R objective.

Project proposals shall address inter/multidisciplinary research in infectious diseases (including those of zoonotic origin) and food, water and vector-borne diseases. Each project proposal must seek the translation from basic scientific findings to intervention and/or implementation.

Call budget Topic 2: 2.5 M €
Call opens: December 2, 2016
Application deadline: March 9, 2017

Find out more

Funder: The European Union’s Horizon 2020 Research and Innovation Programme

Co-fund on “One Health” (zoonoses–emerging threats)

The overall objective is to create a European joint program to deal with “one health”, in particular zoonoses and related emerging threats.

The main emphasis will be on food-borne microbial infections and intoxications, including natural toxins and the risks associated with domesticated and wild animal reservoirs and their exposure routes towards human infection, in order to improve preparedness against future ‘one health’ risks. Related emerging threats such as antimicrobial resistance will be addressed. In order to enhance the ‘one health’ approach to the food chain, important non zoonotic food-borne pathogens transmitted via the food chain will also be considered.

Call budget: up to 45M €
Call opens: October 4, 2016
Application deadline: February 14, 2017

Find out more

Funder: The Canadian Institutes of Health Research (CIHR)

Improved Immunization Coverage Initiative

The Canadian Institutes of Health Research, in partnership with the Public Health Agency of Canada (PHAC) will launch a funding opportunity in September to support research to identify under- and un-immunized sub-populations in Canada, and the factors associated with lower immunization access and uptake in these groups. This initiative will examine the systemic barriers impacting immunization coverage in children and women of reproductive age, and will include support specifically for research focused on First Nations, Inuit and Métis populations, as well as recent newcomers to Canada.

Sponsors: The CIHR Institutes of Infection and Immunity (III) and Population and Public Health (IPPH) in partnership with the Public Health Agency of Canada (PHAC)

Eligibility: Research studies conducted in Canada. Nominated Principal Applicant must be appointed at an eligible institution.

Call budget: CAN$1.2M
Call opens: September 8, 2016
Application deadline: December 6, 2016
Funding start date: February 1, 2017

Find out more

Funder: Public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA)

Innovative Medicines Initiative 2 Call 9 – Joint influenza vaccine effectiveness studies

The scope of the action includes the development and validation of a sustainable governance model for the evaluation of type/brand-specific seasonal influenza vaccine effectiveness in Europe, through collaboration between public and private partners.

It is expected that the action will result in better information for healthcare professionals and the general public about the performance of the influenza vaccines in use, better information on the performance of national immunization programs, improved understanding of the benefits of influenza vaccination, and better understanding of the factors that impact influenza vaccine effectiveness.

Application deadline stage 1: 26th July 2016

Find out more

Funder: Public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA)

Innovative Medicines Initiative 2 Call 8

Ebola and other filoviral haemorrhagic fevers (Ebola+) program: future outbreaks

The scope is to capture emerging scientific advances and to progress those rapidly into health care interventions. Proposals may address aspects of pre-clinical development and/or Phase 1, 2, and 3 clinical developments of vaccines (in particular multivalent), treatments and diagnosis of Ebola or other filovirus infections. Manufacturing strategies, vaccine stability during transport and storage, and/or deployment of vaccines and treatments are also in scope. Proposals for the development of adaptable platforms, which in addition to filoviruses can address multiple other priority pathogens, are also eligible.

Next deadline: 15th September 2016

Find out more

Funder: The European & Developing Countries Clinical Trials Partnership (EDCTP), a public-public partnership between countries in Europe and sub-Saharan Africa, and the European Union
The following calls are funded by EDCTP, which covers the following diseases within its scope:HIV, tuberculosis, malaria, neglected infectious diseases (Buruli ulcer; cysticercosis/taeniasis; dengue; dracunculiasis; echinococcosis; foodborne trematodiases; Hansen disease; human African trypanosomiasis; leishmaniasis; lymphatic filariasis; mycetoma; onchocerciasis; rabies; schistosomiasis; soil-transmitted helminthiases; trachoma; yaws); diarrhoeal diseases; lower respiratory tract infections, as well as emerging infectious diseases of particular relevance for Africa, such as Ebola virus disease or yellow fever.

Vaccines for poverty-related diseases (PRDs)

The purpose of this call is to support large-scale collaborative projects which include one or more clinical trials (phase I to IV) aiming to accelerate the clinical development of new vaccines (preventive or therapeutic) against one of the PRDs. Applications must include at least one clinical trial which will be carried out in sub-Saharan Africa to test the safety, immunogenicity and/or efficacy of the vaccine(s).

Call budget: 70M €
Maximum funding: 15M €
Letter of intent deadline: 13th October 2016
Full proposal deadline: 16th March 2017

Find out more

Funder: The European & Developing Countries Clinical Trials Partnership (EDCTP), a public-public partnership between countries in Europe and sub-Saharan Africa, and the European Union

Research and clinical management of patients in PRD epidemics in sub-Saharan Africa

This call for proposals aims to support the establishment of a multidisciplinary consortium able to provide accelerated evidence for the optimal clinical management of patients and for guiding the public health response to any severe infectious outbreak caused by pathogens within the scope of the EDCTP program with pandemic potential or that may cause significant damage to health and socio-economics in Africa (including antimicrobial-resistant pathogens).

Based on a comprehensive ‘inter-epidemic’ work program, the consortium should ensure preparedness to perform coordinated large-scale multi-site clinical studies in response to an emerging threat. These clinical trials could include studies evaluating potential preventive or therapeutic interventions in a community or health-care setting; validation of diagnostic devices and observational clinical studies aimed at establishing the natural history and determinants of severity of the disease.

Call budget: 10M €
Maximum funding: 10M €
Letter of intent deadline: 29th September 2016
Full proposal deadline: 2nd March 2017

Find out more

Funder: The European & Developing Countries Clinical Trials Partnership (EDCTP), a public-public partnership between countries in Europe and sub-Saharan Africa, and the European Union

Strategic actions supporting large-scale clinical trials

The purpose of this call for proposals is to support distinct strategic actions (clinical research activities) which are part of a large-scale clinical trial that has the potential to achieve rapid advances in the clinical development of new or improved medical interventions against PRDs.

Applications for a strategic action should focus on clinical trials on PRDs in sub-Saharan Africa, and may address any disease within the scope of the EDCTP program. Proposals that include phase III trials are encouraged.

Call budget: € 28M
Maximum funding: € 15M
Letter of intent deadline: 13th October 2016
Full proposal deadline: 16th March 2017

Find out more

Funder: The European & Developing Countries Clinical Trials Partnership (EDCTP), a public-public partnership between countries in Europe and sub-Saharan Africa, and the European Union

Clinical trials and operational research studies to optimize the use of products for poverty-related diseases in mothers, newborns, children and/or adolescents

This call aims to support actions on preventive and therapeutic clinical interventions of post-registration products, as well as related behavioral studies, aimed at optimizing use of new or improved products or combination of products for mothers, newborns, children and/or adolescents.

The scope of this call is limited to clinical trials and operational studies with a product focus.

Activities may include: studies on product (drugs, vaccines, microbicides and diagnostics) development, delivery, uptake and adherence; and strategies for equitable and full-scale access to diagnostics, prevention and treatment interventions. This includes community-based interventions/approaches and qualitative studies. Assessment of behavior of those who would benefit from such products (or interventions) in terms of access to the health care system and uptake of the product/intervention, with adherence to product use, is within scope of this call.

Call budget: 10M €
Maximum funding: 3M €
Letter of intent deadline: 6th September 2016
Full proposal deadline: 2nd March 2017

Find out more

Funder: The European & Developing Countries Clinical Trials Partnership (EDCTP), a public-public partnership between countries in Europe and sub-Saharan Africa, and the European Union

Strategic actions supporting health systems/services optimization research capacities in cooperation with development assistance initiatives

The purpose of this Call for Proposals is to support distinct strategic actions (Coordination & Support Actions) which are part of a large-scale program of actions that is supported by EU, national and/or international development assistance initiatives and/or other funders, including relevant WHO initiatives where appropriate, for strengthening the capacity of health systems to effectively deliver new products and to monitor their post-market safety. This should lead to better planning for the introduction of new medical interventions for PRDs; improved delivery; and, better understanding of the safety profile of and reporting mechanisms for products introduced in sub-Saharan Africa.

Call budget: € 10M
Maximum funding: € 3M
Letter of intent deadline: 29th September 2016
Full proposal deadline: 2nd March 2017

Find out more

Funder: The Canadian Institutes of Health Research (CIHR)

Team Grant: Canada-Latin America-Caribbean Zika Virus Program

The Canadian Institutes of Health research (CIHR) and the International Development Research Centre (IDRC), working with parameters set out by members of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) are planning to invest $3 million CAD in areas where new knowledge on Zika virus will help develop diagnostics for Zika virus infection, understand the pathology caused by the virus, and ultimately prevent its transmission and morbidity.

Application Deadline: July 12, 2016

Find out more

USAID Global Health Challenge BAA

The U.S. Agency for International Development (USAID) Broad Agency Announcement (BAA) seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address the most pressing problems in global health. The United States Agency for International Development (USAID) invites organizations and companies to participate with USAID, in cooperation with its partners, to generate novel tools and approaches that accelerate and sustain improved health outcomes in developing countries.

Deadlines to apply (depending on submissions type): May 20, 2016 (Zika-focused) and June 17, 2016 (other)

Find out more

Funder: Public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA)

Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) has launched a new, open Call for proposals in the area of Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks.

This Call, the second under the Ebola+ programme, provides an opportunity to capture emerging scientific advances and to progress those rapidly into healthcare interventions. As such, the key deliverables of projects funded under the Ebola+ programme must be outputs that will increase our preparedness to react to future outbreaks of Ebola and other filoviral haemorrhagic fevers.

The Call will remain open for two years, with the first cut-off date at March 16, 2016

Find out more